Vir Biotechnology Statistics
Share Statistics
Vir Biotechnology has 138.24M
shares outstanding. The number of shares has increased by 0.8%
in one year.
| Shares Outstanding | 138.24M |
| Shares Change (YoY) | 0.8% |
| Shares Change (QoQ) | -0.42% |
| Owned by Institutions (%) | 64.98% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 220 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 10.31M, so 7.47% of the outstanding
shares have been sold short.
| Short Interest | 10.31M |
| Short % of Shares Out | 7.47% |
| Short % of Float | 12.08% |
| Short Ratio (days to cover) | 11.32 |
Valuation Ratios
The PE ratio is -1.92 and the forward
PE ratio is -1.53.
Vir Biotechnology's PEG ratio is
0.12.
| PE Ratio | -1.92 |
| Forward PE | -1.53 |
| PS Ratio | 13.48 |
| Forward PS | 0.8 |
| PB Ratio | 0.87 |
| P/FCF Ratio | -2.2 |
| PEG Ratio | 0.12 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Vir Biotechnology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.71,
with a Debt / Equity ratio of 0.09.
| Current Ratio | 8.71 |
| Quick Ratio | 8.71 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.18 |
| Debt / FCF | -0.22 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $181,875 |
| Profits Per Employee | $-1,279,313.73 |
| Employee Count | 408 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.15M |
| Effective Tax Rate | 0.22% |
Stock Price Statistics
The stock price has increased by -55.09% in the
last 52 weeks. The beta is 1.36, so Vir Biotechnology's
price volatility has been higher than the market average.
| Beta | 1.36 |
| 52-Week Price Change | -55.09% |
| 50-Day Moving Average | 6.24 |
| 200-Day Moving Average | 7.95 |
| Relative Strength Index (RSI) | 27.79 |
| Average Volume (20 Days) | 1,274,183 |
Income Statement
In the last 12 months, Vir Biotechnology had revenue of 74.2M
and earned -521.96M
in profits. Earnings per share was -3.83.
| Revenue | 74.2M |
| Gross Profit | 73.36M |
| Operating Income | -587.16M |
| Net Income | -521.96M |
| EBITDA | -537.61M |
| EBIT | -552.17M |
| Earnings Per Share (EPS) | -3.83 |
Full Income StatementBalance Sheet
The company has 312.33M in cash and 97.89M in
debt, giving a net cash position of 214.44M.
| Cash & Cash Equivalents | 312.33M |
| Total Debt | 97.89M |
| Net Cash | 214.44M |
| Retained Earnings | -759.78M |
| Total Assets | 1.4B |
| Working Capital | 922.8M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -446.35M
and capital expenditures -7.3M, giving a free cash flow of -453.65M.
| Operating Cash Flow | -446.35M |
| Capital Expenditures | -7.3M |
| Free Cash Flow | -453.65M |
| FCF Per Share | -3.33 |
Full Cash Flow StatementMargins
Gross margin is 98.86%, with operating and profit margins of -791.27% and -703.4%.
| Gross Margin | 98.86% |
| Operating Margin | -791.27% |
| Pretax Margin | -704.95% |
| Profit Margin | -703.4% |
| EBITDA Margin | -724.49% |
| EBIT Margin | -791.27% |
| FCF Margin | -611.35% |
